Session » SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

Date: Saturday, November 6, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0354

A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0325

A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0341

Addition of Narrative Text Abstraction to ICD-Based Abstraction Significantly Improves Identification of Lupus Nephritis in Real-World Data

8:30AM-10:30AM: Abstract Number: 0344

Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0345

Anti-MPP-1 Autoantibodies in Systemic Lupus Erythematosus: A Potential Biomarker for Neuropsychiatric Manifestations

8:30AM-10:30AM: Abstract Number: 0326

Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations

8:30AM-10:30AM: Abstract Number: 0334

Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study

8:30AM-10:30AM: Abstract Number: 0350

EPI-SIGN: Epigenetic SLE Indicators of Glomerular Nephritis

8:30AM-10:30AM: Abstract Number: 0351

Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study

8:30AM-10:30AM: Abstract Number: 0327

Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency

8:30AM-10:30AM: Abstract Number: 0347

Longitudinal ANA Titers in SLE and ANA+ Controls

8:30AM-10:30AM: Abstract Number: 0324

Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World

8:30AM-10:30AM: Abstract Number: 0352

Native American and African American Rheumatic Disease Patients Exhibit Accelerated Biological Aging Compared to European Americans

8:30AM-10:30AM: Abstract Number: 0328

Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records

8:30AM-10:30AM: Abstract Number: 0343

Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry

8:30AM-10:30AM: Abstract Number: 0349

Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort

8:30AM-10:30AM: Abstract Number: 0335

Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey

8:30AM-10:30AM: Abstract Number: 0332

Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018

8:30AM-10:30AM: Abstract Number: 0329

Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort

8:30AM-10:30AM: Abstract Number: 0342

RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 0337

Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record

8:30AM-10:30AM: Abstract Number: 0323

Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients

8:30AM-10:30AM: Abstract Number: 0330

Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)

8:30AM-10:30AM: Abstract Number: 0338

Serum and Urine Galectin-9, IP-10 and SIGLEC-1 as Biomarkers of Disease Activity in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0353

Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 0346

The CB-CAPillaryTM Test Kit: A Tool for Point-of-Care Assays to Measure Cell-Bound Complement Activation Products

8:30AM-10:30AM: Abstract Number: 0336

The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE

8:30AM-10:30AM: Abstract Number: 0348

The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes

8:30AM-10:30AM: Abstract Number: 0356

The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease

8:30AM-10:30AM: Abstract Number: 0339

Trends in Disparity by Age, Sex and Race for Systemic Lupus Erythematosus Patients

8:30AM-10:30AM: Abstract Number: 0340

Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 0331

Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity

8:30AM-10:30AM: Abstract Number: 0355

Utilization of a Clinical Data Research Network to Assess Systemic Lupus International Collaborating Clinics Classification Criteria Attributes in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 0333

Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].